Biogen

Neurology + immunology

BIIB · Nasdaq · United States

Share price · BIIB

$251.41+38.86 (+18.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BIIB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026-3.4%
  2. 22 Oct 2026+5.3%
  3. 14 Jul 2026-8.2%
  4. 13 Jul 2026+5.0%
  5. 14 May 2026-6.4%
  6. 29 Apr 2026+6.0%
  7. 20 Apr 2026+3.4%
  8. 6 Feb 2026+8.5%
  9. 4 Feb 2026+4.9%

    Nothing announced by BIIB that day or the session before.

  10. 14 Jan 2026-5.0%

Share of unusual movement by asset

For each asset, the share of BIIB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lecanemab (Leqembi)
events and moves
5123%
Zorevunersen
events and moves
112%
Diranersen
events and moves
4shown from 8 days
Pegcetacoplan (Empaveli)
events and moves
4shown from 8 days
BIIB122 / DNL151 (LRRK2 inhibitor)
events and moves
1shown from 8 days
Pegcetacoplan ophthalmic (Syfovre)
events and moves
1shown from 8 days
Litifilimab
events and moves
1shown from 8 days
Tofersen (Qalsody)
events and moves
1shown from 8 days
Felzartamab
events and moves
1shown from 8 days
Rituximab (Rituxan)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—12%
Sessions with no dated event—56%

Assets

(20 total)
20Total Assets
11Approved
4Phase 3 / Filed
5Phase 1–2 / Early
18Diseases
Quick filter:
Showing 20 of 20 assets
Target & Modality
Approved
Nrf2 pathway (fumaric acid ester)Small molecule
Multiple Sclerosis
Approved
Nrf2 pathway (fumaric acid ester)Small molecule
Multiple Sclerosis
Approved
Type I Interferon receptor (IFNAR)Biologic (subtype unspecified)
Multiple Sclerosis
Lecanemab(Leqembi)
Approved
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
natalizumab(Tysabri)
Approved
α4 integrinMonoclonal antibody
Inflammatory Bowel DiseaseMultiple Sclerosis
Crohn's Disease
Nusinersen(Spinraza)
Approved
SMN2 pre-mRNARNA / oligonucleotide
Spinal Muscular Atrophy
Pegcetacoplan(Empaveli)
Approved
Complement C3Peptide
Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria
Approved
Complement C3 · Complement C3 / C3bPeptide
Age-Related Macular Degeneration
Approved
Type I interferon receptor · Interferon beta receptor (type I IFN signaling)Biologic (subtype unspecified)
Multiple Sclerosis
Rituximab(Rituxan)
Approved
CD20 · CD20-directed Cytolytic AntibodyMonoclonal antibody
Rheumatoid ArthritisDiffuse Large B-Cell LymphomaFollicular LymphomaChronic Lymphocytic Leukemia
Tofersen(Qalsody)
Approved
SOD1RNA / oligonucleotide
Amyotrophic Lateral Sclerosis
Phase 3
LRRK2Small molecule
Parkinson's Disease
Phase 3
CD38Monoclonal antibody
Multiple MyelomaIgA NephropathyPrimary Membranous Nephropathy
Phase 3
BDCA2 (CLEC4C) · BDCA2 / CD303 (blood dendritic cell antigen 2)Monoclonal antibody
Systemic Lupus Erythematosus
Phase 3
SCN1A mRNARNA / oligonucleotide
Dravet Syndrome

Discontinued programmes (2)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Est. primary completion 2026-12-01 · NCT03758989 · CT.gov ↗
What to watch
FelzartamabPhase 3Antibody-mediated Rejection
Est. primary completion 2026-12-01 · NCT06685757 · CT.gov ↗
What to watch
Lecanemab · LeqembiPhase 2Alzheimer's Disease
Est. primary completion 2026-12-03 · NCT06602258 · CT.gov ↗
What to watch
Lecanemab · LeqembiPhase 3Early Alzheimer's Disease
Est. primary completion 2026-12-31 · NCT03887455 · CT.gov ↗
What to watch
2027 (9)
March 2027 (2)
BIIB122 / DNL151 (LRRK2 inhibitor)Phase 2Parkinson Disease
Est. primary completion 2027-03 · NCT06602193 · CT.gov ↗
What to watch
ZorevunersenPhase 3Dravet Syndrome
Est. primary completion 2027-03 · NCT06872125 · CT.gov ↗
What to watch
May 2027 (2)
peginterferon beta-1a · PlegridyPhase 3Multiple Sclerosis, Relapsing-Remitting
Est. primary completion 2027-05-20 · NCT03958877 · CT.gov ↗
What to watch
FelzartamabPhase 3Immunoglobulin A Nephropathy (IgAN)
Est. primary completion 2027-05-31 · NCT06935357 · CT.gov ↗
What to watch
July 2027 (2)
Pegcetacoplan · EmpaveliPhase 3C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) …
Est. primary completion 2027-07 · NCT05809531 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 2DLBCL, Lymphoma, B-Cell
Est. primary completion 2027-07-31 · NCT04594798 · CT.gov ↗
What to watch
August 2027 (1)
Tofersen · QalsodyPhase 3Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Est. primary completion 2027-08-07 · NCT04856982 · CT.gov ↗
What to watch
September 2027 (1)
Nusinersen · SpinrazaPhase 3Spinal Muscular Atrophy
Est. primary completion 2027-09-24 · NCT05067790 · CT.gov ↗
What to watch
October 2027 (1)
Rituximab · RituxanPhase 3Large B-Cell Lymphoma
Est. primary completion 2027-10-01 · NCT06047080 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
FelzartamabPhase 2Graves' Disease
Est. primary completion 2028-01-31 · NCT07722546 · CT.gov ↗
What to watch
February 2028 (1)
FelzartamabPhase 2Microvascular Inflammation
Est. primary completion 2028-02-10 · NCT07219043 · CT.gov ↗
What to watch
August 2028 (1)
FelzartamabPhase 2Immunoglobulin A Nephropathy
Est. primary completion 2028-08-13 · NCT07889362 · CT.gov ↗
What to watch
September 2028 (1)
FelzartamabPhase 2Generalized Myasthenia Gravis
Est. primary completion 2028-09-19 · NCT07939802 · CT.gov ↗
What to watch
December 2028 (2)
Pegcetacoplan · EmpaveliPhase 2Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Est. primary completion 2028-12 · NCT04901936 · CT.gov ↗
What to watch
Lecanemab · LeqembiPhase 3Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Est. primary completion 2028-12-21 · NCT04468659 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
ZorevunersenPhase 2Dravet Syndrome
Est. primary completion 2029-03-31 · NCT04740476 · CT.gov ↗
What to watch
June 2029 (1)
LitifilimabPhase 3Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Est. primary completion 2029-06-26 · NCT06044337 · CT.gov ↗
What to watch
November 2029 (1)
Rituximab · RituxanPhase 1/2Mature B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
FelzartamabPhase 3Primary Membranous Nephropathy
Est. primary completion 2030-01-28 · NCT06962800 · CT.gov ↗
What to watch
2031 (2)
January 2031 (1)
Pegcetacoplan · EmpaveliPhase 3C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) …
Est. primary completion 2031-01-17 · NCT07898774 · CT.gov ↗
What to watch
December 2031 (1)
FelzartamabPhase 3Antibody-mediated Rejection, Microvascular Inflammation
Est. primary completion 2031-12-31 · NCT07444489 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
LitifilimabPhase 3Systemic Lupus Erythematosus (SLE)
Est. primary completion 2032-05-03 · NCT05352919 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Diroximel fumarate · VumerityPhase 3Relapsing Forms of Multiple Sclerosis
Est. primary completion 2034-07-28 · NCT07483632 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(20)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 September 2026ApprovalLecanemabNMPA approves Leqembi subcutaneous formulation as initiation treatment in China
CN, NMPA · Source ↗
September 2026ApprovalLecanemabJapan approves the LEQEMBI Pen subcutaneous formulation
JP, MHLW/PMDA · Eisai · Source ↗
24 August 2026FDA action dateLecanemabFDA extends PDUFA date for LEQEMBI IQLIK starting dose sBLA to August 24, 2026
US, FDA · Source ↗
13 July 2026ApprovalLecanemabFDA approves LEQEMBI IQLIK subcutaneous initiation dose in early Alzheimer's
US, FDA · Source ↗
24 May 2026FDA action dateLecanemabPDUFA action date set for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
21 May 2026Topline resultBIIB122 (DNL151)Phase 2b LUMA (NCT05348785) did not meet its primary or secondary endpoints; development in idiopathic PD discontinued
Biogen and Denali Therapeutics · Source ↗
14 May 2026Topline resultDiranersenPhase 2 CELIA of diranersen in early Alzheimer's disease did not meet its primary dose-response endpoint
Biogen (announced also by partner Ionis Pharmaceuticals) · Source ↗
25 January 2026Filing acceptedLecanemabFDA accepts sBLA for LEQEMBI IQLIK subcutaneous starting dose
US, FDA · Source ↗
25 January 2026Priority reviewLecanemabPriority Review granted for LEQEMBI IQLIK starting dose sBLA
US, FDA · Source ↗
January 2026Filing acceptedLecanemabChina accepts BLA for subcutaneous LEQEMBI
CN, NMPA · Source ↗
25 November 2025Filing submittedLecanemabRolling sBLA submission completed for LEQEMBI IQLIK starting dose
US, FDA · Source ↗
14 November 2025ApprovalLecanemabMHRA approves LEQEMBI IV maintenance dosing in the UK
UK, MHRA · Source ↗

The 12 most recent of 20 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$2.8B$574M$1.3B+ $0 short-term inv.$21M$641M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$2.7B$530M$1.3B+ $0 short-term inv.—$449M operating cash flowreport ↗
2026-Q1$2.5B$539M$3.4B+ $900M short-term inv.—$646M operating cash flowreport ↗
2025-Q3$2.5B$436M$3.9B+ $98M short-term inv.—$1.3B operating cash flowreport ↗
2025-Q2$2.6B$399M$2.8B—$161M operating cash flowreport ↗
2025-Q1$2.4B$434M$2.6B—$259M operating cash flowreport ↗
2024-Q3$2.5B$543M$1.7B—$936M operating cash flowreport ↗
2024-Q2$2.5B$514M$1.9B—$626M operating cash flowreport ↗
2024-Q1$2.3B$453M$1.1B—$553M operating cash flowreport ↗
2023-Q3$2.5B$736M$2.3B+ $0 short-term inv.$68M$592M operating cash flowreport ↗
2023-Q2$2.5B$584M$2.6B+ $3.5B short-term inv.—$487M operating cash flowreport ↗
2023-Q1$2.5B$571M$2.9B+ $2.1B short-term inv.—$455M operating cash flowreport ↗
2022-Q3$2.5B$549M$3.7B+ $1.2B short-term inv.—$661M operating cash flowreport ↗
2022-Q2$2.6B$529M$2.6B+ $2.2B short-term inv.—$737M operating cash flowreport ↗
2022-Q1$2.5B$552M$1.7B+ $2.0B short-term inv.—$162M operating cash flowreport ↗
2021-Q3$2.8B$702M$1.5B+ $1.4B short-term inv.—$805M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$9.9B$1.8B$3.0B+ $807M short-term inv.—$2.2B operating cash flowreport ↗

Biogen reported full-year 2025 revenue of $9,890.6M, up 2.2% YoY, with R&D spend of $1,778.6M, down 12.9% YoY. Cash and equivalents were $3,008.5M, and net income attributable to Biogen was $1,292.9M. Reported GAAP diluted EPS was $8.79, while non-GAAP diluted EPS was $15.28, exceeding the company’s full-year 2025 non-GAAP guidance range of $14.50 to $15.00.

For 2026, Biogen guided non-GAAP diluted EPS of $15.25 to $16.25 and expects total revenue to decline by a mid-single digit percentage versus 2025. Key pipeline and regulatory events include FDA Priority Review for LEQEMBI IQLIK subcutaneous treatment initiation with a PDUFA date of May 24, 2026, Breakthrough Therapy Designation for litifilimab in cutaneous lupus, expected Phase 3 systemic lupus readouts in Q4 2026, high-dose SPINRAZA approvals in Japan and the E.U. with a U.S. PDUFA of April 3, 2026, and initiation of a Phase 1 study for the BTK degrader BIIB145 in autoimmune diseases.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$9.7B$2.0B$2.4B+ $0 short-term inv.—$2.9B operating cash flowreport ↗
2023-FY$9.8B$2.5B$1.0B+ $0 short-term inv.—$1.5B operating cash flowreport ↗
2022-FY$10.2B$2.2B$3.4B+ $1.5B short-term inv.—$1.4B operating cash flowreport ↗
2021-FY$11.0B$2.5B$2.3B+ $1.5B short-term inv.—$3.6B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($585), 4 sales ($905K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-30Grogan Jane · Head of ResearchOption exercise695——Form 4
2026-10-30Grogan Jane · Head of ResearchTax withholding345$253.62$87KForm 4
2026-10-30Grogan Jane · Head of ResearchOption exercise (derivative)695——Form 4
2026-10-02Godbout Sean · Chief Accounting OfficerOption exercise27——Form 4
2026-10-02Godbout Sean · Chief Accounting OfficerTax withholding8$219.88$2KForm 4
2026-10-02Godbout Sean · Chief Accounting OfficerOption exercise (derivative)27——Form 4
2026-10-01Godbout Sean · Chief Accounting OfficerAward / grant (derivative)985——Form 4
2026-09-01Parini Michael · Chief Legal OfficerAward / grant (derivative)7,405——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 990 reporting institutions held 134.2M shares ($23.7B, 90.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.15,974,601$2.9B
2PRIMECAP MANAGEMENT CO/CA/14,757,607$2.7B
3FMR LLC12,807,541$2.3B
4VANGUARD CAPITAL MANAGEMENT LLC9,537,417$1.7B
5STATE STREET CORP7,167,922$1.3B
6VANGUARD PORTFOLIO MANAGEMENT LLC6,531,727$1.2B
7GEODE CAPITAL MANAGEMENT, LLC4,342,602$793.4M
8WELLINGTON MANAGEMENT GROUP LLP2,961,641$543.0M
9MORGAN STANLEY2,170,940$398.0M
10JPMORGAN CHASE & CO2,016,009$378.1M
11AQR CAPITAL MANAGEMENT LLC1,923,557$346.2M
12Invesco Ltd.1,745,255$320.0M
13Boston Partners1,700,078$311.7M
14NORTHERN TRUST CORP1,446,579$265.2M
15UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1,377,568$252.5M